Tuesday, March 22, 2016 7:23:04 PM
OBMP
http://oncbiomune.com/
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe
OBMP announced that the Company has received a Notice of Allowance for a patent on ProscaVax™, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from the European Patent Office.
The patent, titled "Composition and Method for Treating Cancer," application number 12701292.0, expands the scope of protection of OncBioMune's intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company's vaccine and paclitaxel gallium transferrin (PGT) technologies.
ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune recently disclosed that while the Phase 1 trial is completed, a Phase 2 trial is expected to be initiated later this year evaluating ProscaVax as a front-line treatment for prostate cancer patients at disease presentation.
OBMP
http://oncbiomune.com/
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe
OBMP announced that the Company has received a Notice of Allowance for a patent on ProscaVax™, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from the European Patent Office.
The patent, titled "Composition and Method for Treating Cancer," application number 12701292.0, expands the scope of protection of OncBioMune's intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company's vaccine and paclitaxel gallium transferrin (PGT) technologies.
ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune recently disclosed that while the Phase 1 trial is completed, a Phase 2 trial is expected to be initiated later this year evaluating ProscaVax as a front-line treatment for prostate cancer patients at disease presentation.
OBMP
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
